Human genetic disorders of sphingolipid biosynthesis
- 955 Downloads
Monogenic defects of sphingolipid biosynthesis have been recently identified in human patients. These enzyme deficiencies affect the synthesis of sphingolipid precursors, ceramides or complex glycosphingolipids. They are transmitted as autosomal recessive or dominant traits, and their resulting phenotypes often replicate the abnormalities seen in murine models deficient for the corresponding enzymes. In quite good agreement with the known critical roles of sphingolipids in cells from the nervous system and the epidermis, these genetic defects clinically manifest as neurological disorders, including paraplegia, epilepsy or peripheral neuropathies, or present with ichthyosis. The present review summarizes the genetic alterations, biochemical changes and clinical symptoms of this new group of inherited metabolic disorders. Hypotheses regarding the molecular pathophysiology and potential treatments of these diseases are also discussed.
KeywordsCeramides Hereditary Spastic Paraplegia Sphingoid Base Ceramide Synthases GBA2 Mutation
Autosomal recessive congenital ichthyosis
Hereditary sensory and autonomic neuropathy
Magnetic resonance imaging
This work was supported by INSERM, Université Paul Sabatier, ANR (SphingoDR program), RITC, LNCC (Equipe Labellisée 2013), CHU Toulouse, and the Vaincre les Maladies Lysosomales Foundation (for TL’s group), and the Gebert Rüf Foundation, the Center for Integrative Human Physiology (ZIHP, University of Zurich), “radiz” – Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, and the European Commission (LSHM-CT-2006-037631) (for TH’s group).
Compliance with Ethics Guidelines
Conflict of Interest
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- Dyck PJ (1993) Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In P J Dyck, K P Thomas, J W Griffin, P A Low, & J F Poduslo (Eds), Peripheral Neuropathy (3rd Editio, pp 1065–1093) Saunders PhilladelphiaGoogle Scholar
- Hellberg A, Poole J, Olsson ML (2002) Molecular basis of the globoside-deficient P (k) blood group phenotype. Identification of four inactivating mutations in the UDP-N-acetylgalactosamine: globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase gene. J Biol Chem 277(33):29455–29459PubMedCrossRefGoogle Scholar
- Keusch JJ, Manzella SM, Nyame KA, Cummings RD, Baenziger JU (2000) Cloning of Gb3 synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1, 4-glycosyltransferases conserved in plants, insects, and mammals. J Biol Chem 275(33):25315–25321PubMedCrossRefGoogle Scholar
- Laurá M, Eichler F, Hornemann T, et al (2012) Hereditary sensory and autonomic neuropathy type 1: correlation of severity and plasma atypical deoxy-sphyngoid bases. J Neurol Neurosurg Psychiatry 2012 83 (e1)Google Scholar
- Liao X, Luo Y, Zhan Z, et al (2013) SPG35 contributes to the second common subtype of AR-HSP in China: frequency analysis and functional characterization of FA2H gene mutations. Clin GenetGoogle Scholar
- Mosbech M, Olsen A, Neess D, et al (2014) Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. Ann Clin Transl Neurol in pressGoogle Scholar
- Rautenstrauss B, Neitzel B, Muench C, Haas J, Holinski-Feder E (2009) Late onset hereditary sensory neuropathy type 1 (HSN1) caused by a novel p. C133R missense mutation in SPTLC1. Würzburg, Germany. In: 2009 Meeting of the Peripheral Nerve Society July 4–8, 2009 (p 290 of 381)Google Scholar
- Vanni N, Fruscione F, Ferlazzo E et al. (2014) Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Ann Neurol (in press)Google Scholar
- Wakil SM, Monies DM, Ramzan K, et al (2013) Novel B4GALNT1 mutations in a complicated form of hereditary spastic paraplegia. Clin GenetGoogle Scholar
- Zitomer NC, Mitchell T, Voss KA et al (2009) Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 284(8):4786–4795PubMedCentralPubMedCrossRefGoogle Scholar